Irish Journal of Medical Science

, Volume 180, Issue 1, pp 47–50 | Cite as

Pneumococcal meningitis: clinical outcomes in a pre-vaccine era at a Dublin paediatric hospital, 1999–2007

  • J. M. Lucey
  • P. Gavin
  • M. Cafferkey
  • K. M. Butler
Original Article



To document the long-term outcomes of pneumococcal meningitis in children presenting to a Dublin paediatric hospital in the pre-pneumococcal conjugate vaccine (PCV7) era (1998–2007).


Subjects with pneumococcal meningitis were identified at The Children’s University Hospital, Dublin through the hospital surveillance system and laboratory archives.


44 children were identified with S. pneumoniae meningitis. Mean age of presentation was 23.45 months (2 days to 13 years) and 28 (65%) cases were less than 12 months old. Eight (18.6%) children died. 55% of cases were left with significant deficits. Of the survivors, 7 (20%) had moderate to severe neurological sequelae.


Pneumococcal meningitis is a devastating childhood disease with significant mortality and morbidity, especially in those less than 2 years of age. These data provide a baseline against which the impact of PCV7 on pneumococcal meningitis can be measured.


Streptococcal pneumoniae meningitis Pneumococcal meningitis Pneumococcal conjugate vaccine Paediatric 


  1. 1.
    Jefferson T, Ferroni E, Curtale F et al (2006) Streptococcus pneumoniae in Western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect Dis 6:405–410CrossRefPubMedGoogle Scholar
  2. 2.
    Swartz MN (2004) Bacterial meningitis—a view of the past 90 years. N Engl J Med 351:1826–1828CrossRefPubMedGoogle Scholar
  3. 3.
    Arditi M, Mason EO, Bradley JS et al (1998) Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 102:1087–1097CrossRefPubMedGoogle Scholar
  4. 4.
    Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002; 35: 547–55Google Scholar
  5. 5.
    Hausdorff WP, Bryant J, Paradiso PR et al (2000) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part 1. Clin Infect Dis 30:100–121CrossRefPubMedGoogle Scholar
  6. 6.
    Hausdorff WP, Bryant J, Kloek C et al (2000) The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part 2. Clin Infect Dis 30:122–140CrossRefPubMedGoogle Scholar
  7. 7.
    Fitzsimons JJ, Chong AL, Cafferkey MT, Butler KM (2008) Invasive pneumococcal disease in children in Ireland—the anticipated benefit of conjugate pneumococcal vaccination. IrJ Med Sci. 177(3):225–231 Epub 2008 Jun 27CrossRefGoogle Scholar
  8. 8.
    McIntyre PB, Macintyre CR, Gilmour R, Wang H (2005) A population based study of the impact of corticosteroid therapy and delayed diagnosis on the outcome of childhood pneumococcal meningitis. Arch Dis Child 90(4):391–396CrossRefPubMedGoogle Scholar
  9. 9.
    van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004405Google Scholar
  10. 10.
    Centers for Disease Control and Prevention (CDC) (2008) Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction–eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 57(6):144–148Google Scholar
  11. 11.
    Perrocheau A, De Benoist AC, Six C et al (2002) Epidemiology of bacterial meningitis in France in 1999. Ann Med Interne 153:311–317Google Scholar
  12. 12.
    Ada G (2001) Vaccines and vaccination. N Engl J Med 345(14):1042–1053CrossRefPubMedGoogle Scholar
  13. 13.
    Musher DM (2006) Pneumococcal vaccine—direct and indirect (“herd”) effects. N Engl J Med 354(14):1522–1524CrossRefPubMedGoogle Scholar
  14. 14.
    Hicks LA, Harrison LH, Flannery B et al (2007) Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 196(9):1346–1354 Epub 2007 Oct 4CrossRefPubMedGoogle Scholar
  15. 15.
    Scott DA, Komjathy SF, Hu BT, Baker S, Supan LA, Monahan CA, Gruber W, Siber GR, Lockhart SP (2007) Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25(33):6164–6166 Epub 2007 Jun 26CrossRefPubMedGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2010

Authors and Affiliations

  • J. M. Lucey
    • 1
    • 3
  • P. Gavin
    • 1
  • M. Cafferkey
    • 1
    • 2
  • K. M. Butler
    • 1
  1. 1.Department of PaediatricsChildren’s University HospitalDublin 1Ireland
  2. 2.Department of Clinical MicrobiologyChildren’s University HospitalDublin 1Ireland
  3. 3.Department of PaediatricsPrincess Margaret Children’s HospitalPerthAustralia

Personalised recommendations